ViiV Healthcare, a global specialist HIV company majority-owned by GSK, in collaboration with United States-based Pfizer Inc and Japan-based Shionogi Limited as shareholders have revealed positive Week 48 results from the phase III TANGO study of dolutegravir plus lamivudine, it was reported yesterday.
The TANGO study was conducted to evaluate whether adults living with HIV-1 who had maintained viral suppression for around six months on a tenofovir alafenamide fumarate-containing regimen of around three drugs, were able to maintain similar rates of viral suppression after switching to the 2-drug regimen of dolutegravir plus lamivudine in a fixed dose combination, compared to continuing the tenofovir alafenamide fumarate -containing regimen. The study met its primary endpoint for non-inferiority, based on the proportion of participants with plasma HIV-1 RNA up to 50 copies per millilitre using the FDA Snapshot algorithm at Week 48.
No patients met confirmed virologic withdrawal criteria or developed treatment resistance in the dolutegravir plus lamivudine arm of the study. The safety results for the 2DR of dolutegravir plus lamivudine were consistent with the product labelling for the medicines. The complete results from the study will be presented at the 10th International AIDS Society Conference on HIV Science to be held from 21 July to 24 July in Mexico City.
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML